Target genes of differentially methylated enhancers were notably enriched in developmental pathways, various gene sets of known transcription factor (TF) targets (ETS2 proto-oncogene, FOXO4 tumour suppressor), and in prostate cancer-associated pathways (Dataset EV14). This evidence concerns the gene ETS2 and prostate carcinoma.